FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012454728> ?p ?o ?g. }

• W2012454728 endingPage "1239" @default.
• W2012454728 startingPage "1234" @default.
• W2012454728 abstract "The goals of the present study were to assess the efficacy and safety of nalmefene (Cervene) in patients with acute (< or =6 hours) ischemic stroke and to investigate the safety of combined recombinant tissue plasminogen activator and nalmefene in a separate subset of patients. Nalmefene, an opioid antagonist with relative kappa receptor selectivity, has shown neuroprotective effects in multiple experimental central nervous system injury and ischemic models. Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients <70 years old.This investigation was a phase III, placebo-controlled, double-blind, randomized study of a 24-hour infusion of nalmefene. Patients with acute ischemic stroke who had an onset of symptoms within 6 hours and a baseline score of > or =4 on the NIH Stroke Scale were randomized to receive either 60 mg nalmefene administered as a 10-mg bolus over 15 minutes and then a 50-mg infusion over 23.75 hours or placebo. The primary efficacy outcome was the proportion of patients achieving a score of > or =60 on the Barthel Index and a rating of moderate disability or better on the Glasgow Outcome Scale at 12 weeks. Assessments were performed at baseline (predose), hours 12 and 24, days 2 and 7, and week 12.A total of 368 patients were randomized at 42 centers, including 32 patients treated with recombinant tissue plasminogen activator and study drug. Nalmefene was well tolerated. Overall, there was no significant difference in 3-month functional outcome for nalmefene treatment compared with placebo on any of the planned analyses. A prospective secondary analysis also failed to find a treatment effect in patients <70 years old.Although nalmefene appears to be safe and well tolerated, this study failed to find any treatment benefit in stroke patients treated within 6 hours." @default.
• W2012454728 created "2016-06-24" @default.
• W2012454728 creator A5003394099 @default.
• W2012454728 creator A5008726438 @default.
• W2012454728 creator A5038327931 @default.
• W2012454728 creator A5077612823 @default.
• W2012454728 date "2000-06-01" @default.
• W2012454728 modified "2023-09-26" @default.
• W2012454728 title "Cervene (Nalmefene) in Acute Ischemic Stroke" @default.
• W2012454728 cites W1874700596 @default.
• W2012454728 cites W1968205083 @default.
• W2012454728 cites W1970029670 @default.
• W2012454728 cites W1986343337 @default.
• W2012454728 cites W1995514548 @default.
• W2012454728 cites W2026918087 @default.
• W2012454728 cites W2027550745 @default.
• W2012454728 cites W2042550512 @default.
• W2012454728 cites W2044547224 @default.
• W2012454728 cites W2051572660 @default.
• W2012454728 cites W2061179393 @default.
• W2012454728 cites W2070949149 @default.
• W2012454728 cites W2071984852 @default.
• W2012454728 cites W2108803055 @default.
• W2012454728 cites W2113920766 @default.
• W2012454728 cites W2134955467 @default.
• W2012454728 cites W2138595885 @default.
• W2012454728 cites W2292308933 @default.
• W2012454728 cites W4243621358 @default.
• W2012454728 cites W4300539464 @default.
• W2012454728 doi "https://doi.org/10.1161/01.str.31.6.1234" @default.
• W2012454728 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10835438" @default.
• W2012454728 hasPublicationYear "2000" @default.
• W2012454728 type Work @default.
• W2012454728 sameAs 2012454728 @default.
• W2012454728 citedByCount "79" @default.
• W2012454728 countsByYear W20124547282012 @default.
• W2012454728 countsByYear W20124547282013 @default.
• W2012454728 countsByYear W20124547282014 @default.
• W2012454728 countsByYear W20124547282015 @default.
• W2012454728 countsByYear W20124547282016 @default.
• W2012454728 countsByYear W20124547282017 @default.
• W2012454728 countsByYear W20124547282018 @default.
• W2012454728 countsByYear W20124547282019 @default.
• W2012454728 countsByYear W20124547282020 @default.
• W2012454728 countsByYear W20124547282021 @default.
• W2012454728 countsByYear W20124547282022 @default.
• W2012454728 crossrefType "journal-article" @default.
• W2012454728 hasAuthorship W2012454728A5003394099 @default.
• W2012454728 hasAuthorship W2012454728A5008726438 @default.
• W2012454728 hasAuthorship W2012454728A5038327931 @default.
• W2012454728 hasAuthorship W2012454728A5077612823 @default.
• W2012454728 hasBestOaLocation W20124547281 @default.
• W2012454728 hasConcept C126322002 @default.
• W2012454728 hasConcept C127413603 @default.
• W2012454728 hasConcept C141071460 @default.
• W2012454728 hasConcept C142724271 @default.
• W2012454728 hasConcept C168563851 @default.
• W2012454728 hasConcept C170493617 @default.
• W2012454728 hasConcept C204787440 @default.
• W2012454728 hasConcept C27081682 @default.
• W2012454728 hasConcept C2776572282 @default.
• W2012454728 hasConcept C2776885963 @default.
• W2012454728 hasConcept C2777972943 @default.
• W2012454728 hasConcept C2778836221 @default.
• W2012454728 hasConcept C2780645631 @default.
• W2012454728 hasConcept C42219234 @default.
• W2012454728 hasConcept C71924100 @default.
• W2012454728 hasConcept C78519656 @default.
• W2012454728 hasConceptScore W2012454728C126322002 @default.
• W2012454728 hasConceptScore W2012454728C127413603 @default.
• W2012454728 hasConceptScore W2012454728C141071460 @default.
• W2012454728 hasConceptScore W2012454728C142724271 @default.
• W2012454728 hasConceptScore W2012454728C168563851 @default.
• W2012454728 hasConceptScore W2012454728C170493617 @default.
• W2012454728 hasConceptScore W2012454728C204787440 @default.
• W2012454728 hasConceptScore W2012454728C27081682 @default.
• W2012454728 hasConceptScore W2012454728C2776572282 @default.
• W2012454728 hasConceptScore W2012454728C2776885963 @default.
• W2012454728 hasConceptScore W2012454728C2777972943 @default.
• W2012454728 hasConceptScore W2012454728C2778836221 @default.
• W2012454728 hasConceptScore W2012454728C2780645631 @default.
• W2012454728 hasConceptScore W2012454728C42219234 @default.
• W2012454728 hasConceptScore W2012454728C71924100 @default.
• W2012454728 hasConceptScore W2012454728C78519656 @default.
• W2012454728 hasIssue "6" @default.
• W2012454728 hasLocation W20124547281 @default.
• W2012454728 hasLocation W20124547282 @default.
• W2012454728 hasOpenAccess W2012454728 @default.
• W2012454728 hasPrimaryLocation W20124547281 @default.
• W2012454728 hasRelatedWork W1998087325 @default.
• W2012454728 hasRelatedWork W2002120878 @default.
• W2012454728 hasRelatedWork W2003938723 @default.
• W2012454728 hasRelatedWork W2047967234 @default.
• W2012454728 hasRelatedWork W2118496982 @default.
• W2012454728 hasRelatedWork W2125230596 @default.
• W2012454728 hasRelatedWork W2439875401 @default.
• W2012454728 hasRelatedWork W4238867864 @default.
• W2012454728 hasRelatedWork W2519357708 @default.

• next